Two Dose Levels of Privigen in Pediatric CIDP
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age2-17
SponsorCSL Behring
About this trial
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Eligibility criteria
Qualifiers
- Male or female subjects 2 to ≤ 17 years of age with confirmed or possible CIDP.
Disqualifiers
- Absence of CIDP symptoms
-History or family history of inherited neuropathy
-Diagnosed developmental delay or regression
-History of thrombotic episode
Trial design
Treatments tested in this trial
- IgPro10
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov